BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 24258498)

  • 21. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
    Passamonti F; Palandri F; Saydam G; Callum J; Devos T; Guglielmelli P; Vannucchi AM; Zor E; Zuurman M; Gilotti G; Zhang Y; Griesshammer M
    Lancet Haematol; 2022 Jul; 9(7):e480-e492. PubMed ID: 35597252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ruxolitinib for the treatment of patients with polycythemia vera.
    Kiladjian JJ; Winton EF; Talpaz M; Verstovsek S
    Expert Rev Hematol; 2015 Aug; 8(4):391-401. PubMed ID: 25980454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
    Foltz L; Pica GM; Zerazhi H; Van Droogenbroeck J; Visanica S; Báez de la Fuente E; Leber B; de Almeida AM; Ranta D; Kiladjian JJ; Chrit L; Kandra A; Morando J; Devos T
    Leuk Lymphoma; 2019 Dec; 60(14):3493-3502. PubMed ID: 31359808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.
    Altomare I; Parasuraman S; Paranagama D; Kish J; Lord K; Yu J; Colucci P
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e915-e921. PubMed ID: 34353779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
    Nazha A; Gerds AT
    Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
    Van Den Neste E; André M; Gastinne T; Stamatoullas A; Haioun C; Belhabri A; Reman O; Casasnovas O; Ghesquieres H; Verhoef G; Claessen MJ; Poirel HA; Copin MC; Dubois R; Vandenberghe P; Stoian IA; Cottereau AS; Bailly S; Knoops L; Morschhauser F
    Haematologica; 2018 May; 103(5):840-848. PubMed ID: 29351986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
    Eliaçık E; Işık A; Aksu S; Üner A; Büyükaşık Y; Sayınalp N; Göker H; Özcebe OI; Haznedaroğlu İC
    Turk J Haematol; 2015 Jun; 32(2):163-7. PubMed ID: 26316485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
    Coltoff A; Mesa R; Gotlib J; Shulman J; Rampal RK; Siwoski O; Yacoub A; Moliterno A; Yang A; Braunstein E; Gerds AT; Hobbs GS; Winton EF; Goel S; Wadleigh M; Tremblay D; Moshier E; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):697-703.e1. PubMed ID: 32624445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
    Mesa R; Vannucchi AM; Yacoub A; Zachee P; Garg M; Lyons R; Koschmieder S; Rinaldi C; Byrne J; Hasan Y; Passamonti F; Verstovsek S; Hunter D; Jones MM; Zhen H; Habr D; Martino B
    Br J Haematol; 2017 Jan; 176(1):76-85. PubMed ID: 27858987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
    Reiter A; Harrison C
    Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.
    Kuykendall AT
    Ann Hematol; 2023 May; 102(5):985-993. PubMed ID: 36944847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.
    Mascarenhas J; Passamonti F; Burbury K; El-Galaly TC; Gerds A; Gupta V; Higgins B; Wonde K; Jamois C; Kovic B; Huw LY; Katakam S; Maffioli M; Mesa R; Palmer J; Bellini M; Ross DM; Vannucchi AM; Yacoub A
    Blood Adv; 2022 Feb; 6(4):1162-1174. PubMed ID: 34933330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
    Maffioli M; Mora B; Passamonti F
    Clin Adv Hematol Oncol; 2017 Sep; 15(9):700-707. PubMed ID: 28949941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera: A case report.
    Al-Mashdali AF; Kashgary WR; Yassin MA
    Medicine (Baltimore); 2021 Nov; 100(44):e27722. PubMed ID: 34871267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.
    Mesa RA
    IDrugs; 2010 Jun; 13(6):394-403. PubMed ID: 20506062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A safety evaluation of ruxolitinib for the treatment of polycythemia vera.
    Boldrini V; Vannucchi AM; Guglielmelli P
    Expert Opin Drug Saf; 2024 Jan; 23(1):1-7. PubMed ID: 38156903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
    Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
    Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.